|
1
|
Jimba S, Nakagami T, Takahashi M,
Wakamatsu T, Hirota Y, Iwamoto Y and Wasada T: Prevalence of
non-alcoholic fatty liver disease and its association with impaired
glucose metabolism in Japanese adults. Diabet Med. 22:1141–1145.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan JG and Farrell GC: Epidemiology of
non-alcoholic fatty liver disease in China. J Hepatol. 50:204–210.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amarapurkar DN, Hashimoto E, Lesmana LA,
Sollano JD, Chen PJ and Goh KL: Asia-Pacific Working Party on
NAFLD: How common is non-alcoholic fatty liver disease in the
Asia-Pacific region and are there local differences? J
Gastroenterol Hepatol. 22:788–793. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hjortnaes J, Algra A, Olijhoek J, Huisman
M, Jacobs J, van der Graaf Y and Visseren F: Serum uric acid levels
and risk for vascular diseases in patients with metabolic syndrome.
J Rheumatol. 34:1882–1887. 2007.PubMed/NCBI
|
|
5
|
Choi HK and Ford ES: Prevalence of the
metabolic syndrome in individuals with hyperuricemia. Am J Med.
120:442–447. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, Xu C, Yu C, Xu L and Miao M:
Association of serum uric acid level with non-alcoholic fatty liver
disease: A cross-sectional study. J Hepatol. 50:1029–1034. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sirota JC, McFann K, Targher G, Johnson
RJ, Chonchol M and Jalal DI: Elevated serum uric acid levels are
associated with non-alcoholic fatty liver disease independently of
metabolic syndrome features in the United States: Liver ultrasound
data from the National Health and Nutrition Examination Survey.
Metabolism. 62:392–399. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee YJ, Lee HR, Lee JH, Shin YH and Shim
JY: Association between serum uric acid and non-alcoholic fatty
liver disease in Korean adults. Clin Chem Lab Med. 48:175–180.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu C, Yu C, Xu L, Miao M and Li Y: High
serum uric acid increases the risk for nonalcoholic Fatty liver
disease: A prospective observational study. PLoS One. 5:e115782010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lanaspa MA, Sanchez-Lozada LG, Choi YJ,
Cicerchi C, Kanbay M, Roncal-Jimenez CA, Ishimoto T, Li N, Marek G,
Duranay M, et al: Uric acid induces hepatic steatosis by generation
of mitochondrial oxidative stress: Potential role in
fructose-dependent and -independent fatty liver. J Biol Chem.
287:40732–40744. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baldwin W, McRae S, Marek G, Wymer D,
Pannu V, Baylis C, Johnson RJ and Sautin YY: Hyperuricemia as a
mediator of the proinflammatory endocrine imbalance in the adipose
tissue in a murine model of the metabolic syndrome. Diabetes.
60:1258–1269. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Petta S, Cammà C, Cabibi D, Di Marco V and
Craxì A: Hyperuricemia is associated with histological liver damage
in patients with non-alcoholic fatty liver disease. Aliment
Pharmacol Ther. 34:757–766. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Flegal KM, Carroll MD, Kit BK and Ogden
CL: Prevalence of obesity and trends in the distribution of body
mass index among US adults, 1999–2010. JAMA. 307:491–497. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reynolds K, Gu D, Whelton PK, Wu X, Duan
X, Mo J and He J: InterASIA Collaborative Group: Prevalence and
risk factors of overweight and obesity in China. Obesity (Silver
Spring). 15:10–18. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grundy SM, Brewer HB Jr, Cleeman JI, Smith
SC Jr and Lenfant C: American Heart Association, National Heart,
Lung, and Blood Institute: Definition of metabolic syndrome: Report
of the National Heart, Lung, and Blood Institute/American Heart
Association conference on scientific issues related to definition.
Circulation. 109:433–438. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang J and Alderman MH: Serum uric acid
and cardiovascular mortality the NHANES I epidemiologic follow-up
study, 1971–1992. National Health and Nutrition Examination Survey.
JAMA. 283:2404–2410. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kleiner DE, Brunt EM, Van Natta M, Behling
C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS,
Unalp-Arida A, et al: Nonalcoholic Steatohepatitis Clinical
Research Network: Design and validation of a histological scoring
system for nonalcoholic fatty liver disease. Hepatology.
41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sautin YY, Nakagawa T, Zharikov S and
Johnson RJ: Adverse effects of the classic antioxidant uric acid in
adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am
J Physiol Cell Physiol. 293:C584–C596. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu CF, Yu CH, Xu L, Sa XY and Li YM:
Hypouricemic therapy: A novel potential therapeutic option for
nonalcoholic fatty liver disease. Hepatology. 52:1865–1866. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Crane JK and Mongiardo KM:
Pro-inflammatory effects of uric acid in the gastrointestinal
tract. Immunol Invest. 43:255–266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martinon F: Signaling by ROS drives
inflammasome activation. Eur J Immunol. 40:616–619. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vandanmagsar B, Youm YH, Ravussin A,
Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM and Dixit
VD: The NLRP3 inflammasome instigates obesity-induced inflammation
and insulin resistance. Nat Med. 17:179–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim SM, Lee SH, Kim YG, Kim SY, Seo JW,
Choi YW, Kim DJ, Jeong KH, Lee TW, Ihm CG, et al:
Hyperuricemia-induced NLRP3 activation of macrophages contributes
to the progression of diabetic nephropathy. Am J Physiol Renal
Physiol. 308:F993–F1003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iracheta-Vellve A, Petrasek J,
Satishchandran A, Gyongyosi B, Saha B, Kodys K, Fitzgerald KA,
Kurt-Jones EA and Szabo G: Inhibition of sterile danger signals,
uric acid and ATP, prevents inflammasome activation and protects
from alcoholic steatohepatitis in mice. J Hepatol. 63:1147–1155.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kanbay M, Huddam B, Azak A, Solak Y,
Kadioglu GK, Kirbas I, Duranay M, Covic A and Johnson RJ: A
randomized study of allopurinol on endothelial function and
estimated glomular filtration rate in asymptomatic hyperuricemic
subjects with normal renal function. Clin J Am Soc Nephrol.
6:1887–1894. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ogino K, Kato M, Furuse Y, Kinugasa Y,
Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, et
al: Uric acid-lowering treatment with benzbromarone in patients
with heart failure: A double-blind placebo-controlled crossover
preliminary study. Circ Heart Fail. 3:73–81. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kanbay M, Ozkara A, Selcoki Y, Isik B,
Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R and Covic A: Effect
of treatment of hyperuricemia with allopurinol on blood pressure,
creatinine clearence, and proteinuria in patients with normal renal
functions. Int Urol Nephrol. 39:1227–1233. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Afzali A, Weiss NS, Boyko EJ and Ioannou
GN: Association between serum uric acid level and chronic liver
disease in the United States. Hepatology. 52:578–589. 2010.
View Article : Google Scholar : PubMed/NCBI
|
